Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$46.55 USD
-0.83 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $46.57 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AGIO 46.55 -0.83(-1.75%)
Will AGIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for
Other News for AGIO
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
Agios Pharmaceuticals announces FDA granted ODD to AG-946
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Small-cap and mid-cap Health Care has room to rally - Roth MKM